Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives

Conclusions MRI-guided intravenous r-tPA for patients with AIS with an unknown time of onset is cost-effective in China and cost-saving in the USA.

http://bmjopen.bmj.com/cgi/content/short/12/11/e065133?rss=1

Source: BMJ Open - November 14, 2022 Category: General Medicine Authors: Zhao, S., Cheng, Y., Tong, X., Han, M., Ji, L., Che, Y., Hu, W., Liu, A. Tags: Open access, Neurology Source Type: research